Chlorpromazine inhibits the glucocorticoid receptor-mediated gene transcription in a calcium-dependent manner

Neuropharmacology

Volumn 43, Issue 6, 2002, Pages 1035-1043

  Basta Kaim, A ^a   Budziszewska, B ^a   Jaworska Feil, L ^a   Tetich, M ^a   Leskiewicz M ^a   Kubera, M ^a   Lason W ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Chlorpromazine; Fibroblast cells; GR mediated gene transcription; Kinase modulators; Phospholipase 1

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ADENOSINE 3',5' PHOSPHOROTHIOATE; CALCIMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM ION; CALCIUM IONOPHORE; CHLORPROMAZINE; CLOZAPINE; FORSKOLIN; HALOPERIDOL; HISTAMINE; ISOENZYME; MEPYRAMINE MALEATE; N (4 AMINOBUTYL) 5 CHLORO 2 NAPSYLAMIDE; NEUROLEPTIC AGENT; NIFEDIPINE; PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; PHOSPHOLIPASE BETA 1; PHOSPHOLIPASE C; PHOSPHOLIPASE C INHIBITOR; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C ALPHA; RACLOPRIDE; REMOXIPRIDE; SULPIRIDE; U 107; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FIBROBLAST; GENETIC TRANSCRIPTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTIPSYCHOTIC AGENTS; CALCIMYCIN; CALCIUM; CALCIUM CHANNEL BLOCKERS; CELL LINE; CELL LINE, TRANSFORMED; CHLORAMPHENICOL O-ACETYLTRANSFERASE; CHLORPROMAZINE; CLOZAPINE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME INHIBITORS; ESTRENES; FIBROBLASTS; FORSKOLIN; GENE EXPRESSION REGULATION; GENES, REPORTER; HALOPERIDOL; HISTAMINE; HISTAMINE H1 ANTAGONISTS; IONOPHORES; MAMMARY TUMOR VIRUS, MOUSE; MICE; NIFEDIPINE; PHORBOL ESTERS; PHOSPHODIESTERASE INHIBITORS; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; PYRILAMINE; PYRROLIDINONES; RACLOPRIDE; RECEPTORS, GLUCOCORTICOID; REMOXIPRIDE; SULFONAMIDES; SULPIRIDE; TETRADECANOYLPHORBOL ACETATE; THIONUCLEOTIDES; TRANSCRIPTION, GENETIC;

EID: 0036848022     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00149-1     Document Type: Article

References (36)

1. Adcock I.M., Nasuhara Y., Stevens D.A., Barnes P.J. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kB and lack of I-kB involvement. Brain Journal of Pharmacology. 127:1999;1003-1011.
2. Beaudry G., Langlois M.-C., Weppe I., Rouillard C., Lévesque D. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. Journal of Neurochemistry. 75:2000;1694-1702.
3. Berrettini W.H., Nadi N.S., Gershon E.S. Absence of specific binding of several putative neurotransmitters to human fibroblasts. Journal of Receptors Research. 3:1983;409-421.
4. Bloch M., Gur E., Shalev A. Chlorpromazine prophylaxis of steroid-induced psychosis. General Hospital Psychiatry. 16:1994;42-44.
5. Budziszewska B., Basta-Kaim A., Jaworska-Feil L., Tetich M., Leśkiewicz M., Kubera M., Lasoń W. Effects of neuroleptic drugs on glucocorticoid receptor-mediated gene transcription. Polish Journal of Pharmacology. 53:2001;171.
6. Budziszewska B., Jaworska-Feil L., Kajta M., Lasoń W. Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. British Journal of Pharmacology. 130:2000;1385-1393.
7. Chetty M., Gouws E., Miller R., Moodley S.V. The use of a side effect as a qualitative indicator of plasma chlorpromazine levels. European Neuropsychopharmacology. 9:1999;77-82.
8. Dwivedi Y., Pandey G.N. Effects of treatment with haloperidol, chlorpromazine, and clozapine on protein kinase C (PKC) and phosphoinositide-specific phospholipase C (PI-PLC) activity and on mRNA and protein expression of PKC and PLC isozymes in rat brain. Journal of Pharmacology and Experimental Therapeutics. 291:1999;688-704.
9. Dwivedi Y., Rizavi H.S., Rao J.S., Pandey G.N. Modifications in the phosphoinositide signaling pathway by adrenal glucocorticoids in rat brain: focus on phosphoinositide-specific phospholipase C and inositol 1,4,5-trisphosphate. Journal of Pharmacology and Experimental Therapeutics. 295:2000;244-254.
10. Farooqui S.M., Prasad C. An antibody to dopamine D2 receptor inhibits dopamine antagonist and agonist binding to dopamine D2 receptor cDNA transfected mouse fibroblast cells. Life Sciences. 51:1992;1509-1516.
11. Feldman R.S., Meyer J.S., Quenzer L.F. Schizophrenia. Principles of Neuropsychopharmacology. 1996;783-818 Sinauer Associates Inc. Sunderland, MA.
12. Gur R.E., Pearlson G.D. Neuroimaging in schizophrenia research. Schizophrenia Bulletin. 19:1993;337-353.
13. Horácek J. Novel antipsychotics and extrapyramidal side effects. Theory and reality. Pharmacopsychiatry. 33:2000;34-42.
14. Kornhuber J., Retz W., Riederer P. Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? Journal of Neural Transmission Supplementum. 46:1995;315-323.
15. Kornhuber J., Schultz A., Wiltfang J., Meineke I., Gleiter C.H., Zochling R., Boissl K.W., Leblhuber F., Riederer P. Persistence of haloperidol in human brain tissue. American Journal of Psychiatry. 156:1999;885-890.
16. Lammers C.H., Garcia-Borreguero D., Schmider J., Gotthard U., Dettling M., Holsboer F., Heuser I.J.E. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biological Psychiatry. 38:1995;803-807.
17. Ling M.H., Perry P.J., Tsuang M.T. Side effects of corticosteroid therapy. Psychiatric aspects. Archives of General Psychiatry. 38:1981;471-477.
18. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry. 193:1951;265-275.
19. Marinelli M., Piazza P.V., Deroche V., Maccari S., Le Moal M., Simon H. Corticosterone circadian secretion differentially facilitates dopamine-mediated psychomotor effect of cocaine and morphine. Journal of Neuroscience. 14:1994;2724-2731.
20. Marinelli M., Rouge-Pont F., Deroche V., Barrot M., De Jesus-Oliveira C., Le Moal M., Piazza P.V. Glucocorticoids and behavioral effects of psychostimulants. I: Locomotor response to cocaine depends on basal levels of glucocorticoids. Journal of Pharmacology and Experimental Therapeutics. 281:1997;1392-1400.
21. Meshul C.K., Tan S.E. Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity. Synapse. 18:1994;205-217.
22. Milliken G.A., Johnson D.E., 1984. Analysis of messy data. Designed Experiments, vol. I. Van Nostrand Reinhold, New York.
23. Moyer M.L., Borror K.C., Bona B.J., Defranco D.B., Nordeen S.K. Modulation of cell signaling pathways can enhance or impair glucocorticoid-induced gene expression without altering the state of receptor phosphorylation. Journal of Biological Chemistry. 268:1993;22933-22940.
24. Ning Y.-M., Sanchez E.R. Evidence for a functional interaction between calmodulin and the glucocorticoid receptor. Biochemical and Biophysical Research Communications. 208:1995;48-54.
25. Nordeen S.K., Bona B.J., Moyer M.L. Latent agonist activity of the steroid antagonist, RU486, is unmasked in cells treated with activators of protein kinase A. Molecular Endocrinology. 7:1993;731-742.
26. Nordeen S.K., Moyer M.L., Bona B.J. The coupling of multiple signal transduction pathways with steroid response mechanisms. Endocrinology. 134:1994;1723-1732.
27. Okugawa G., Omori K., Suzukawa J., Fujiseki Y., Kinoshita T., Inagaki C. Long-term treatment with antidepressants increases glucocorticoid receptor binding and gene expression in cultured rat hippocampal neurones. Journal of Neuroendocrinology. 11:1999;887-895.
28. Pariante C.M., Pearce B.D., Pisell T.L., Owens M.J., Miller A.H. Steroid independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Molecular Pharmacology. 52:1997;571-581.
29. Piazza P.V., Barrot M., Rouge-Pont F., Marinelli M., Maccari S., Abrous D.N., Simon H., Le-Moal M. Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Proceedings of the National Academy of Sciences of the United States of America. 93:1996a;15445-15450.
30. Piazza P.V., Rouge-Pont F., Deroche V., Maccari S., Simon H., Le Moal M. Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proceedings of the National Academy of Sciences of the United States of America. 93:1996b;8716-8720.
31. Post A., Holsboer F., Behl C. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. Journal of Neuroscience. 18:1998;8236-8246.
32. Reagan L.P., McEwen B.S. Controversies surrounding glucocorticoid-mediated cell death in the hippocampus. Journal of Chemical Neuroanatomy. 13:1997;149-167.
33. Seeman P., Tallerico T., Corbett P., Van Tol H.H.M., Kamboj R.K. Role of D2/D4 and serotonin (2A) receptors in antipsychotic and anticataleptic action. Journal of Psychopharmacology. 11:1997;15-17.
34. Wik G., Wiesel F.A., Eneroth P., Sedvall G., Astrom G. Dexamethasone suppression test in schizophrenic patients before and during neuroleptic treatment. Acta Psychiatrica Scandinavica. 74:1986;161-167.
35. Wyatt R.J., Henter I.D. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. Journal of Psychiatry Research. 32:1998;169-177.
36. Zhang S.P., Prozialeck W.C., Weiss B. Differential inhibition of calcium-dependent and calmodulin-dependent enzymes by drug-calmodulin adducts. Molecular Pharmacology. 38:1990;698-704.